MODERN BIO / TESTING LAB / PRECISION ONCOLOGY
Emerging + use-dependentRGCC International offers liquid-biopsy and molecular tests that examine circulating tumor cells and related cancer signals. Some are positioned for early detection; others for monitoring known cancer or exploring treatment sensitivity. Those are different decisions with different evidence, risks and follow-up needs.
01 / CHOOSE THE CLINICAL LANE
02 / RGCC TEST MAP
Designed by RGCC for early-detection risk signals before symptoms.
Keep in view: Does not diagnose cancer, cover every cancer or replace organ-specific screening.
Evaluates circulating tumor cell count, phenotype and stemness markers.
Keep in view: Interpret changes with tumor type, stage, treatment, imaging and the same laboratory method.
Measures the presence and concentration of circulating tumor cells.
Keep in view: A count alone does not establish treatment success, recurrence or progression.
Tracks markers associated with selected cancers, including breast, colon, GI, lung, melanoma, prostate and sarcoma.
Keep in view: Availability and clinical fit depend on the confirmed cancer type and the treating clinician's plan.
RGCC reports cellular and molecular sensitivity to selected chemotherapy and targeted agents.
Keep in view: An ex-vivo result is one input; it is not a prescription or proof of patient benefit.
Adds RGCC-reported sensitivity to selected natural substances and other modalities.
Keep in view: Natural does not mean safe or compatible. Oncology and pharmacy review are essential.
03 / THE RESPONSIBLE WORKFLOW
Symptoms, no known cancer, confirmed diagnosis, active treatment or post-treatment surveillance.
Pathology, stage, imaging, prior biomarkers, inherited risk, treatments, medicines and supplements.
Confirm that the test can answer a defined question and that the correct oncology team is involved.
Review evidence, limits, privacy, full cost, possible results and downstream diagnostic burden.
Use the exact specimen, handling and shipping requirements for the selected assay.
Compare it with pathology, imaging, authorized biomarkers, symptoms and clinical guidelines.
Confirm, monitor, repeat, refer or take no action—with an owner and timeline for follow-up.
A screening signal is not proof of cancer. It should trigger a coordinated diagnostic pathway, which may include imaging, endoscopy or tissue biopsy depending on the predicted site and clinical context.
A negative blood result does not exclude cancer, clear concerning symptoms or cancel recommended screening. Early cancers may release too little circulating material for detection.
Laboratory response categories must be weighed against the cancer type, stage, patient health, drug approval, dosing evidence, interactions and the treating oncologist's plan.
04 / BEFORE ORDERING
What exact decision will this result change?
Is this intended for screening, monitoring, recurrence surveillance or treatment selection?
What evidence supports this exact test in my cancer type and stage?
What is the test's regulatory and laboratory status where I live?
What are its sensitivity, specificity and false-positive or false-negative risks?
How will a result be confirmed with pathology, imaging or an authorized diagnostic?
Who will interpret the report and own follow-up?
Will my oncologist review it before any treatment or supplement changes?
What is the complete cost, including repeat testing and downstream workup?
How are my sample, genetic data and results stored, shared and deleted?
START WITH WHAT IS ALREADY PROVEN
05 / CHECK THE CLAIM